Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: A single-center experience. (March 2023)

• Record Type: Journal Article
• Authors: Mazzarelli, C.; Costantino, D.; Cesarini, L.; Zavaglia, C.; Rampoldi, A.; Morelli, F.; Cabrini, G.; Capitanio, S.; Zanni, D.; Carboni, C.; Belli, L.S.
• Is Part Of: Digestive and liver disease. Volume 55(2023)Supplement 1
• Page Start: S68
• Publication Date: 2023-03
• Subjects: Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2023.01.135
• Languages: English
• ISSNs: 1590-8658

Abstract

Abstract : Background: Transarterial radioembolization (TARE) has become widely used for the treatment of Hepatocellular carcinoma (HCC). TARE is a microembolic procedure that minimizes alterations to hepatic arterial flow, and thus can be safely performed in patients with HCC and portal vein tumor thrombus (PVTT). Aim: The long-term clinical outcomes of 38 patients with HCC treated with TARE at Niguarda Hospital from 2105 and 2022 were analyzed. Results: Patients were stratified according to the BCLC Staging system. 27 patients (71%) were in advanced stage, 10 (26%) in intermediate stage and 1 in early-stage HCC (3%). All patients had an Eastern Cooperative Oncology Group (ECOG) score of 0-1 and their Child-Pugh class was A-B7. Bilirubin was < 1, 2 mg/dl in 33 patients (87%) and tumor burden was <50% in 35 patients (84%). 24 patients (73%) had a PVVT: ten PV1 (segmental), seven PV2 (second order) and seven PV3 (main right/left). A complete and partial response to treatment was observed in 7 (18%) and 15 patients (40%) respectively. During the follow-up period (mean time 20 months), overall survival (OS) was 39%. Median OS in complete, partial response and tumor progression group was 29 months, 25 months and 6 months respectively. Conclusion: TARE is a potential effective treatment in intermediate to advanced HCC, particularly in the case of PVTT.